Advertisement

Index by author

November 01, 2004; Volume 32,Issue 11

A

  1. Adelsberger, Jennifer K.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  2. Afzelius, Lovisa

    1. STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES
      Lovisa Afzelius, Florian Raubacher, Anders Karlén, Flemming Steen Jørgensen, Tommy B. Andersson, Collen M. Masimirembwa and Ismael Zamora
      Drug Metabolism and Disposition November 2004, 32 (11) 1218-1229; DOI: https://doi.org/10.1124/dmd.32.11.1218

  3. Allers, Paul

    1. VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA
      Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
      Drug Metabolism and Disposition November 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304

  4. Andersson, Tommy B.

    1. STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES
      Lovisa Afzelius, Florian Raubacher, Anders Karlén, Flemming Steen Jørgensen, Tommy B. Andersson, Collen M. Masimirembwa and Ismael Zamora
      Drug Metabolism and Disposition November 2004, 32 (11) 1218-1229; DOI: https://doi.org/10.1124/dmd.32.11.1218

B

  1. Baillie, Thomas A.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  2. Baker, Maribeth P.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  3. Bakhtiar, Ray

    1. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT
      Rosa I. Sanchez, Regina W. Wang, Deborah J. Newton, Ray Bakhtiar, Ping Lu, Shuet-Hing Lee Chiu, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1287-1292; DOI: https://doi.org/10.1124/dmd.104.000216

  4. Ball, Simon E.

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

  5. Benet, Leslie Z.

    1. EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
      Hong Sun, Yong Huang, Lynda Frassetto and Leslie Z. Benet
      Drug Metabolism and Disposition November 2004, 32 (11) 1239-1246; DOI: https://doi.org/10.1124/dmd.104.000521
    2. HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMES
      Justine L. Lam and Leslie Z. Benet
      Drug Metabolism and Disposition November 2004, 32 (11) 1311-1316; DOI: https://doi.org/10.1124/dmd.32.11.1311

  6. Beno, David W. A.

    1. THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS
      Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall and Robert E. Kimura
      Drug Metabolism and Disposition November 2004, 32 (11) 1325-1330; DOI: https://doi.org/10.1124/dmd.104.000927

  7. Booth-Genthe, Catherine L.

    1. HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATION
      Donghui Cui, Catherine L. Booth-Genthe, Edward Carlini, Brian Carr and Michael L. Schrag
      Drug Metabolism and Disposition November 2004, 32 (11) 1260-1264; DOI: https://doi.org/10.1124/dmd.32.11.1260

  8. Brunner, Janice E.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

C

  1. Carlini, Edward

    1. HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATION
      Donghui Cui, Catherine L. Booth-Genthe, Edward Carlini, Brian Carr and Michael L. Schrag
      Drug Metabolism and Disposition November 2004, 32 (11) 1260-1264; DOI: https://doi.org/10.1124/dmd.32.11.1260

  2. Carr, Brian

    1. HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATION
      Donghui Cui, Catherine L. Booth-Genthe, Edward Carlini, Brian Carr and Michael L. Schrag
      Drug Metabolism and Disposition November 2004, 32 (11) 1260-1264; DOI: https://doi.org/10.1124/dmd.32.11.1260

  3. Chen, Yong

    1. THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS
      Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall and Robert E. Kimura
      Drug Metabolism and Disposition November 2004, 32 (11) 1325-1330; DOI: https://doi.org/10.1124/dmd.104.000927

  4. Cherrington, Nathan J.

    1. DOWN-REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDE 4 (Oatp4; Oatp1b2; Slc21a10) mRNA BY LIPOPOLYSACCHARIDE THROUGH THE TOLL-LIKE RECEPTOR 4 (TLR4)
      Ning Li, Supratim Choudhuri, Nathan J. Cherrington and Curtis D. Klaassen
      Drug Metabolism and Disposition November 2004, 32 (11) 1265-1271; DOI: https://doi.org/10.1124/dmd.32.11.1265

  5. Chichester, Clinton O.

    1. DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
      Yuzhong Ma, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester and Bingfang Yan
      Drug Metabolism and Disposition November 2004, 32 (11) 1317-1324; DOI: https://doi.org/10.1124/dmd.104.000786

  6. Chiu, Shuet-Hing Lee

    1. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT
      Rosa I. Sanchez, Regina W. Wang, Deborah J. Newton, Ray Bakhtiar, Ping Lu, Shuet-Hing Lee Chiu, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1287-1292; DOI: https://doi.org/10.1124/dmd.104.000216

  7. Choudhuri, Supratim

    1. DOWN-REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDE 4 (Oatp4; Oatp1b2; Slc21a10) mRNA BY LIPOPOLYSACCHARIDE THROUGH THE TOLL-LIKE RECEPTOR 4 (TLR4)
      Ning Li, Supratim Choudhuri, Nathan J. Cherrington and Curtis D. Klaassen
      Drug Metabolism and Disposition November 2004, 32 (11) 1265-1271; DOI: https://doi.org/10.1124/dmd.32.11.1265

  8. Cui, Donghui

    1. HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATION
      Donghui Cui, Catherine L. Booth-Genthe, Edward Carlini, Brian Carr and Michael L. Schrag
      Drug Metabolism and Disposition November 2004, 32 (11) 1260-1264; DOI: https://doi.org/10.1124/dmd.32.11.1260
    2. SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL
      Michael L. Schrag, Donghui Cui, Thomas H. Rushmore, Magang Shou, Bennett Ma and A. David Rodrigues
      Drug Metabolism and Disposition November 2004, 32 (11) 1299-1303; DOI: https://doi.org/10.1124/dmd.32.11.1299

D

  1. de Almeida, Isabel Tavares

    1. VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA
      Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
      Drug Metabolism and Disposition November 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304

  2. Duran, Marinus

    1. VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA
      Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
      Drug Metabolism and Disposition November 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304

  3. Dybdal, Noel

    1. TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE
      Hong Xiang, Cindy B. Nguyen, Sean K. Kelley, Noel Dybdal and Enrique Escandón
      Drug Metabolism and Disposition November 2004, 32 (11) 1230-1238; DOI: https://doi.org/10.1124/dmd.104.000323

E

  1. Ellis, S. W.

    1. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE
      A. Heydari, K. Rowland Yeo, M. S. Lennard, S. W. Ellis, G. T. Tucker and A. Rostami-Hodjegan
      Drug Metabolism and Disposition November 2004, 32 (11) 1213-1217; DOI: https://doi.org/10.1124/dmd.104.001180

  2. Escandón, Enrique

    1. TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE
      Hong Xiang, Cindy B. Nguyen, Sean K. Kelley, Noel Dybdal and Enrique Escandón
      Drug Metabolism and Disposition November 2004, 32 (11) 1230-1238; DOI: https://doi.org/10.1124/dmd.104.000323

  3. Evans, David C.

    1. THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17α-ETHINYLESTRADIOL
      Bonnie Wang, Rosa I. Sanchez, Ronald B. Franklin, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1209-1212; DOI: https://doi.org/10.1124/dmd.104.000182
    2. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT
      Rosa I. Sanchez, Regina W. Wang, Deborah J. Newton, Ray Bakhtiar, Ping Lu, Shuet-Hing Lee Chiu, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1287-1292; DOI: https://doi.org/10.1124/dmd.104.000216

F

  1. Ford, Michael

    1. DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
      Yuzhong Ma, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester and Bingfang Yan
      Drug Metabolism and Disposition November 2004, 32 (11) 1317-1324; DOI: https://doi.org/10.1124/dmd.104.000786

  2. Franklin, Ronald B.

    1. THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17α-ETHINYLESTRADIOL
      Bonnie Wang, Rosa I. Sanchez, Ronald B. Franklin, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1209-1212; DOI: https://doi.org/10.1124/dmd.104.000182

  3. Frassetto, Lynda

    1. EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
      Hong Sun, Yong Huang, Lynda Frassetto and Leslie Z. Benet
      Drug Metabolism and Disposition November 2004, 32 (11) 1239-1246; DOI: https://doi.org/10.1124/dmd.104.000521

G

  1. Galinsky, Raymond E.

    1. THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS
      Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall and Robert E. Kimura
      Drug Metabolism and Disposition November 2004, 32 (11) 1325-1330; DOI: https://doi.org/10.1124/dmd.104.000927

  2. Giraud, Carole

    1. IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19
      Carole Giraud, Agnès Tran, Elisabeth Rey, Jean Vincent, Jean-Marc Tréluyer and Gérard Pons
      Drug Metabolism and Disposition November 2004, 32 (11) 1279-1286; DOI: https://doi.org/10.1124/dmd.32.11.1279

  3. Goosen, Theunis C.

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

  4. Gross, Gerhard

    1. HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154
      Tappei Takada, H. Markus Weiss, Olivier Kretz, Gerhard Gross and Yuichi Sugiyama
      Drug Metabolism and Disposition November 2004, 32 (11) 1272-1278; DOI: https://doi.org/10.1124/dmd.104.000497

H

  1. Hall, Stephen D.

    1. THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS
      Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall and Robert E. Kimura
      Drug Metabolism and Disposition November 2004, 32 (11) 1325-1330; DOI: https://doi.org/10.1124/dmd.104.000927

  2. Henderson, Paul T.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  3. Heydari, A.

    1. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE
      A. Heydari, K. Rowland Yeo, M. S. Lennard, S. W. Ellis, G. T. Tucker and A. Rostami-Hodjegan
      Drug Metabolism and Disposition November 2004, 32 (11) 1213-1217; DOI: https://doi.org/10.1124/dmd.104.001180

  4. Huang, Yong

    1. EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
      Hong Sun, Yong Huang, Lynda Frassetto and Leslie Z. Benet
      Drug Metabolism and Disposition November 2004, 32 (11) 1239-1246; DOI: https://doi.org/10.1124/dmd.104.000521

  5. Hurst, Susan

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

  6. Huskey, Su-Er W.

    1. THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17α-ETHINYLESTRADIOL
      Bonnie Wang, Rosa I. Sanchez, Ronald B. Franklin, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1209-1212; DOI: https://doi.org/10.1124/dmd.104.000182
    2. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT
      Rosa I. Sanchez, Regina W. Wang, Deborah J. Newton, Ray Bakhtiar, Ping Lu, Shuet-Hing Lee Chiu, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1287-1292; DOI: https://doi.org/10.1124/dmd.104.000216

  7. Hyland, Ruth

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

I

  1. IJlst, Lodewijk

    1. VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA
      Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
      Drug Metabolism and Disposition November 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304

J

  1. Jakobs, Cornelis

    1. VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA
      Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
      Drug Metabolism and Disposition November 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304

  2. Jiyamapa-Serna, Vanida A.

    1. THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS
      Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall and Robert E. Kimura
      Drug Metabolism and Disposition November 2004, 32 (11) 1325-1330; DOI: https://doi.org/10.1124/dmd.104.000927

  3. Jones, Barry C.

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

  4. Jørgensen, Flemming Steen

    1. STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES
      Lovisa Afzelius, Florian Raubacher, Anders Karlén, Flemming Steen Jørgensen, Tommy B. Andersson, Collen M. Masimirembwa and Ismael Zamora
      Drug Metabolism and Disposition November 2004, 32 (11) 1218-1229; DOI: https://doi.org/10.1124/dmd.32.11.1218

K

  1. Karlén, Anders

    1. STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES
      Lovisa Afzelius, Florian Raubacher, Anders Karlén, Flemming Steen Jørgensen, Tommy B. Andersson, Collen M. Masimirembwa and Ismael Zamora
      Drug Metabolism and Disposition November 2004, 32 (11) 1218-1229; DOI: https://doi.org/10.1124/dmd.32.11.1218

  2. Kelley, Sean K.

    1. TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE
      Hong Xiang, Cindy B. Nguyen, Sean K. Kelley, Noel Dybdal and Enrique Escandón
      Drug Metabolism and Disposition November 2004, 32 (11) 1230-1238; DOI: https://doi.org/10.1124/dmd.104.000323

  3. Khan, Ikhlas A.

    1. DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
      Yuzhong Ma, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester and Bingfang Yan
      Drug Metabolism and Disposition November 2004, 32 (11) 1317-1324; DOI: https://doi.org/10.1124/dmd.104.000786

  4. Kimura, Robert E.

    1. THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS
      Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall and Robert E. Kimura
      Drug Metabolism and Disposition November 2004, 32 (11) 1325-1330; DOI: https://doi.org/10.1124/dmd.104.000927

  5. Klaassen, Curtis D.

    1. DOWN-REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDE 4 (Oatp4; Oatp1b2; Slc21a10) mRNA BY LIPOPOLYSACCHARIDE THROUGH THE TOLL-LIKE RECEPTOR 4 (TLR4)
      Ning Li, Supratim Choudhuri, Nathan J. Cherrington and Curtis D. Klaassen
      Drug Metabolism and Disposition November 2004, 32 (11) 1265-1271; DOI: https://doi.org/10.1124/dmd.32.11.1265

  6. Koup, Jeffrey R.

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

  7. Kretz, Olivier

    1. HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154
      Tappei Takada, H. Markus Weiss, Olivier Kretz, Gerhard Gross and Yuichi Sugiyama
      Drug Metabolism and Disposition November 2004, 32 (11) 1272-1278; DOI: https://doi.org/10.1124/dmd.104.000497

  8. Kunta, Jeevan R.

    1. DIFFERENTIATION OF GUT AND HEPATIC FIRST-PASS LOSS OF VERAPAMIL IN INTESTINAL AND VASCULAR ACCESS-PORTED (IVAP) RABBITS
      Jeevan R. Kunta, Sung-Hack Lee, Barbara A. Perry, Yong-Hee Lee and Patrick J. Sinko
      Drug Metabolism and Disposition November 2004, 32 (11) 1293-1298; DOI: https://doi.org/10.1124/dmd.104.000752

L

  1. Lam, Justine L.

    1. HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMES
      Justine L. Lam and Leslie Z. Benet
      Drug Metabolism and Disposition November 2004, 32 (11) 1311-1316; DOI: https://doi.org/10.1124/dmd.32.11.1311

  2. Lee, Sung-Hack

    1. DIFFERENTIATION OF GUT AND HEPATIC FIRST-PASS LOSS OF VERAPAMIL IN INTESTINAL AND VASCULAR ACCESS-PORTED (IVAP) RABBITS
      Jeevan R. Kunta, Sung-Hack Lee, Barbara A. Perry, Yong-Hee Lee and Patrick J. Sinko
      Drug Metabolism and Disposition November 2004, 32 (11) 1293-1298; DOI: https://doi.org/10.1124/dmd.104.000752

  3. Lee, Yong-Hee

    1. DIFFERENTIATION OF GUT AND HEPATIC FIRST-PASS LOSS OF VERAPAMIL IN INTESTINAL AND VASCULAR ACCESS-PORTED (IVAP) RABBITS
      Jeevan R. Kunta, Sung-Hack Lee, Barbara A. Perry, Yong-Hee Lee and Patrick J. Sinko
      Drug Metabolism and Disposition November 2004, 32 (11) 1293-1298; DOI: https://doi.org/10.1124/dmd.104.000752

  4. Lennard, M. S.

    1. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE
      A. Heydari, K. Rowland Yeo, M. S. Lennard, S. W. Ellis, G. T. Tucker and A. Rostami-Hodjegan
      Drug Metabolism and Disposition November 2004, 32 (11) 1213-1217; DOI: https://doi.org/10.1124/dmd.104.001180

  5. Li, Ning

    1. DOWN-REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDE 4 (Oatp4; Oatp1b2; Slc21a10) mRNA BY LIPOPOLYSACCHARIDE THROUGH THE TOLL-LIKE RECEPTOR 4 (TLR4)
      Ning Li, Supratim Choudhuri, Nathan J. Cherrington and Curtis D. Klaassen
      Drug Metabolism and Disposition November 2004, 32 (11) 1265-1271; DOI: https://doi.org/10.1124/dmd.32.11.1265

  6. Liu, Jirong

    1. DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
      Yuzhong Ma, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester and Bingfang Yan
      Drug Metabolism and Disposition November 2004, 32 (11) 1317-1324; DOI: https://doi.org/10.1124/dmd.104.000786

  7. Lu, Ping

    1. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT
      Rosa I. Sanchez, Regina W. Wang, Deborah J. Newton, Ray Bakhtiar, Ping Lu, Shuet-Hing Lee Chiu, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1287-1292; DOI: https://doi.org/10.1124/dmd.104.000216

M

  1. Ma, Bennett

    1. SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL
      Michael L. Schrag, Donghui Cui, Thomas H. Rushmore, Magang Shou, Bennett Ma and A. David Rodrigues
      Drug Metabolism and Disposition November 2004, 32 (11) 1299-1303; DOI: https://doi.org/10.1124/dmd.32.11.1299

  2. Ma, Yuzhong

    1. DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
      Yuzhong Ma, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester and Bingfang Yan
      Drug Metabolism and Disposition November 2004, 32 (11) 1317-1324; DOI: https://doi.org/10.1124/dmd.104.000786

  3. Masimirembwa, Collen M.

    1. STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES
      Lovisa Afzelius, Florian Raubacher, Anders Karlén, Flemming Steen Jørgensen, Tommy B. Andersson, Collen M. Masimirembwa and Ismael Zamora
      Drug Metabolism and Disposition November 2004, 32 (11) 1218-1229; DOI: https://doi.org/10.1124/dmd.32.11.1218

  4. McGinnity, Dermot F.

    1. EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE
      Dermot F. McGinnity, Matthew G. Soars, Richard A. Urbanowicz and Robert J. Riley
      Drug Metabolism and Disposition November 2004, 32 (11) 1247-1253; DOI: https://doi.org/10.1124/dmd.104.000026

N

  1. Newton, Deborah J.

    1. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT
      Rosa I. Sanchez, Regina W. Wang, Deborah J. Newton, Ray Bakhtiar, Ping Lu, Shuet-Hing Lee Chiu, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1287-1292; DOI: https://doi.org/10.1124/dmd.104.000216

  2. Nguyen, Cindy B.

    1. TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE
      Hong Xiang, Cindy B. Nguyen, Sean K. Kelley, Noel Dybdal and Enrique Escandón
      Drug Metabolism and Disposition November 2004, 32 (11) 1230-1238; DOI: https://doi.org/10.1124/dmd.104.000323

P

  1. Pearson, Paul G.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  2. Perry, Barbara A.

    1. DIFFERENTIATION OF GUT AND HEPATIC FIRST-PASS LOSS OF VERAPAMIL IN INTESTINAL AND VASCULAR ACCESS-PORTED (IVAP) RABBITS
      Jeevan R. Kunta, Sung-Hack Lee, Barbara A. Perry, Yong-Hee Lee and Patrick J. Sinko
      Drug Metabolism and Disposition November 2004, 32 (11) 1293-1298; DOI: https://doi.org/10.1124/dmd.104.000752

  3. Peterkin, Vincent

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

  4. Pons, Gérard

    1. IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19
      Carole Giraud, Agnès Tran, Elisabeth Rey, Jean Vincent, Jean-Marc Tréluyer and Gérard Pons
      Drug Metabolism and Disposition November 2004, 32 (11) 1279-1286; DOI: https://doi.org/10.1124/dmd.32.11.1279

R

  1. Raubacher, Florian

    1. STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES
      Lovisa Afzelius, Florian Raubacher, Anders Karlén, Flemming Steen Jørgensen, Tommy B. Andersson, Collen M. Masimirembwa and Ismael Zamora
      Drug Metabolism and Disposition November 2004, 32 (11) 1218-1229; DOI: https://doi.org/10.1124/dmd.32.11.1218

  2. Rey, Elisabeth

    1. IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19
      Carole Giraud, Agnès Tran, Elisabeth Rey, Jean Vincent, Jean-Marc Tréluyer and Gérard Pons
      Drug Metabolism and Disposition November 2004, 32 (11) 1279-1286; DOI: https://doi.org/10.1124/dmd.32.11.1279

  3. Riley, Robert J.

    1. EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE
      Dermot F. McGinnity, Matthew G. Soars, Richard A. Urbanowicz and Robert J. Riley
      Drug Metabolism and Disposition November 2004, 32 (11) 1247-1253; DOI: https://doi.org/10.1124/dmd.104.000026

  4. Rodrigues, A. David

    1. SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL
      Michael L. Schrag, Donghui Cui, Thomas H. Rushmore, Magang Shou, Bennett Ma and A. David Rodrigues
      Drug Metabolism and Disposition November 2004, 32 (11) 1299-1303; DOI: https://doi.org/10.1124/dmd.32.11.1299

  5. Rose, Mark J.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  6. Rostami-Hodjegan, A.

    1. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE
      A. Heydari, K. Rowland Yeo, M. S. Lennard, S. W. Ellis, G. T. Tucker and A. Rostami-Hodjegan
      Drug Metabolism and Disposition November 2004, 32 (11) 1213-1217; DOI: https://doi.org/10.1124/dmd.104.001180

  7. Rushmore, Thomas H.

    1. SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL
      Michael L. Schrag, Donghui Cui, Thomas H. Rushmore, Magang Shou, Bennett Ma and A. David Rodrigues
      Drug Metabolism and Disposition November 2004, 32 (11) 1299-1303; DOI: https://doi.org/10.1124/dmd.32.11.1299

S

  1. Sachdeva, Karuna

    1. DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
      Yuzhong Ma, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester and Bingfang Yan
      Drug Metabolism and Disposition November 2004, 32 (11) 1317-1324; DOI: https://doi.org/10.1124/dmd.104.000786

  2. Sanchez, Rosa I.

    1. THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17α-ETHINYLESTRADIOL
      Bonnie Wang, Rosa I. Sanchez, Ronald B. Franklin, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1209-1212; DOI: https://doi.org/10.1124/dmd.104.000182
    2. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT
      Rosa I. Sanchez, Regina W. Wang, Deborah J. Newton, Ray Bakhtiar, Ping Lu, Shuet-Hing Lee Chiu, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1287-1292; DOI: https://doi.org/10.1124/dmd.104.000216

  3. Sandhu, Punam

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  4. Schrag, Michael L.

    1. HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATION
      Donghui Cui, Catherine L. Booth-Genthe, Edward Carlini, Brian Carr and Michael L. Schrag
      Drug Metabolism and Disposition November 2004, 32 (11) 1260-1264; DOI: https://doi.org/10.1124/dmd.32.11.1260
    2. SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL
      Michael L. Schrag, Donghui Cui, Thomas H. Rushmore, Magang Shou, Bennett Ma and A. David Rodrigues
      Drug Metabolism and Disposition November 2004, 32 (11) 1299-1303; DOI: https://doi.org/10.1124/dmd.32.11.1299

  5. Shou, Magang

    1. SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL
      Michael L. Schrag, Donghui Cui, Thomas H. Rushmore, Magang Shou, Bennett Ma and A. David Rodrigues
      Drug Metabolism and Disposition November 2004, 32 (11) 1299-1303; DOI: https://doi.org/10.1124/dmd.32.11.1299

  6. Silva, Margarida F. B.

    1. VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA
      Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
      Drug Metabolism and Disposition November 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304

  7. Sinko, Patrick J.

    1. DIFFERENTIATION OF GUT AND HEPATIC FIRST-PASS LOSS OF VERAPAMIL IN INTESTINAL AND VASCULAR ACCESS-PORTED (IVAP) RABBITS
      Jeevan R. Kunta, Sung-Hack Lee, Barbara A. Perry, Yong-Hee Lee and Patrick J. Sinko
      Drug Metabolism and Disposition November 2004, 32 (11) 1293-1298; DOI: https://doi.org/10.1124/dmd.104.000752

  8. Smith, Dennis A.

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

  9. Soars, Matthew G.

    1. EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE
      Dermot F. McGinnity, Matthew G. Soars, Richard A. Urbanowicz and Robert J. Riley
      Drug Metabolism and Disposition November 2004, 32 (11) 1247-1253; DOI: https://doi.org/10.1124/dmd.104.000026

  10. Sugiyama, Yuichi

    1. HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154
      Tappei Takada, H. Markus Weiss, Olivier Kretz, Gerhard Gross and Yuichi Sugiyama
      Drug Metabolism and Disposition November 2004, 32 (11) 1272-1278; DOI: https://doi.org/10.1124/dmd.104.000497

  11. Sun, Hong

    1. EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
      Hong Sun, Yong Huang, Lynda Frassetto and Leslie Z. Benet
      Drug Metabolism and Disposition November 2004, 32 (11) 1239-1246; DOI: https://doi.org/10.1124/dmd.104.000521

T

  1. Takada, Tappei

    1. HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154
      Tappei Takada, H. Markus Weiss, Olivier Kretz, Gerhard Gross and Yuichi Sugiyama
      Drug Metabolism and Disposition November 2004, 32 (11) 1272-1278; DOI: https://doi.org/10.1124/dmd.104.000497

  2. Tran, Agnès

    1. IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19
      Carole Giraud, Agnès Tran, Elisabeth Rey, Jean Vincent, Jean-Marc Tréluyer and Gérard Pons
      Drug Metabolism and Disposition November 2004, 32 (11) 1279-1286; DOI: https://doi.org/10.1124/dmd.32.11.1279

  3. Tréluyer, Jean-Marc

    1. IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19
      Carole Giraud, Agnès Tran, Elisabeth Rey, Jean Vincent, Jean-Marc Tréluyer and Gérard Pons
      Drug Metabolism and Disposition November 2004, 32 (11) 1279-1286; DOI: https://doi.org/10.1124/dmd.32.11.1279

  4. Tucker, G. T.

    1. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE
      A. Heydari, K. Rowland Yeo, M. S. Lennard, S. W. Ellis, G. T. Tucker and A. Rostami-Hodjegan
      Drug Metabolism and Disposition November 2004, 32 (11) 1213-1217; DOI: https://doi.org/10.1124/dmd.104.001180

U

  1. Ubick, Esther A.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  2. Uhing, Michael R.

    1. THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS
      Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall and Robert E. Kimura
      Drug Metabolism and Disposition November 2004, 32 (11) 1325-1330; DOI: https://doi.org/10.1124/dmd.104.000927

  3. Urbanowicz, Richard A.

    1. EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE
      Dermot F. McGinnity, Matthew G. Soars, Richard A. Urbanowicz and Robert J. Riley
      Drug Metabolism and Disposition November 2004, 32 (11) 1247-1253; DOI: https://doi.org/10.1124/dmd.104.000026

V

  1. Vincent, Jean

    1. IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19
      Carole Giraud, Agnès Tran, Elisabeth Rey, Jean Vincent, Jean-Marc Tréluyer and Gérard Pons
      Drug Metabolism and Disposition November 2004, 32 (11) 1279-1286; DOI: https://doi.org/10.1124/dmd.32.11.1279

  2. Vogel, John S.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

W

  1. Wallace, Michael A.

    1. EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE
      Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul T. Henderson, Paul G. Pearson and Thomas A. Baillie
      Drug Metabolism and Disposition November 2004, 32 (11) 1254-1259; DOI: https://doi.org/10.1124/dmd.104.000422

  2. Wanders, Ronald J. A.

    1. VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA
      Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
      Drug Metabolism and Disposition November 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304

  3. Wang, Bonnie

    1. THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17α-ETHINYLESTRADIOL
      Bonnie Wang, Rosa I. Sanchez, Ronald B. Franklin, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1209-1212; DOI: https://doi.org/10.1124/dmd.104.000182

  4. Wang, Regina W.

    1. CYTOCHROME P450 3A4 IS THE MAJOR ENZYME INVOLVED IN THE METABOLISM OF THE SUBSTANCE P RECEPTOR ANTAGONIST APREPITANT
      Rosa I. Sanchez, Regina W. Wang, Deborah J. Newton, Ray Bakhtiar, Ping Lu, Shuet-Hing Lee Chiu, David C. Evans and Su-Er W. Huskey
      Drug Metabolism and Disposition November 2004, 32 (11) 1287-1292; DOI: https://doi.org/10.1124/dmd.104.000216

  5. Weiss, H. Markus

    1. HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154
      Tappei Takada, H. Markus Weiss, Olivier Kretz, Gerhard Gross and Yuichi Sugiyama
      Drug Metabolism and Disposition November 2004, 32 (11) 1272-1278; DOI: https://doi.org/10.1124/dmd.104.000497

  6. Williams, J. Andrew

    1. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
      J. Andrew Williams, Ruth Hyland, Barry C. Jones, Dennis A. Smith, Susan Hurst, Theunis C. Goosen, Vincent Peterkin, Jeffrey R. Koup and Simon E. Ball
      Drug Metabolism and Disposition November 2004, 32 (11) 1201-1208; DOI: https://doi.org/10.1124/dmd.104.000794

X

  1. Xiang, Hong

    1. TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE
      Hong Xiang, Cindy B. Nguyen, Sean K. Kelley, Noel Dybdal and Enrique Escandón
      Drug Metabolism and Disposition November 2004, 32 (11) 1230-1238; DOI: https://doi.org/10.1124/dmd.104.000323

Y

  1. Yan, Bingfang

    1. DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
      Yuzhong Ma, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester and Bingfang Yan
      Drug Metabolism and Disposition November 2004, 32 (11) 1317-1324; DOI: https://doi.org/10.1124/dmd.104.000786

  2. Yang, Dongfang

    1. DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
      Yuzhong Ma, Karuna Sachdeva, Jirong Liu, Michael Ford, Dongfang Yang, Ikhlas A. Khan, Clinton O. Chichester and Bingfang Yan
      Drug Metabolism and Disposition November 2004, 32 (11) 1317-1324; DOI: https://doi.org/10.1124/dmd.104.000786

  3. Yeo, K. Rowland

    1. MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE
      A. Heydari, K. Rowland Yeo, M. S. Lennard, S. W. Ellis, G. T. Tucker and A. Rostami-Hodjegan
      Drug Metabolism and Disposition November 2004, 32 (11) 1213-1217; DOI: https://doi.org/10.1124/dmd.104.001180

Z

  1. Zamora, Ismael

    1. STRUCTURAL ANALYSIS OF CYP2C9 AND CYP2C5 AND AN EVALUATION OF COMMONLY USED MOLECULAR MODELING TECHNIQUES
      Lovisa Afzelius, Florian Raubacher, Anders Karlén, Flemming Steen Jørgensen, Tommy B. Andersson, Collen M. Masimirembwa and Ismael Zamora
      Drug Metabolism and Disposition November 2004, 32 (11) 1218-1229; DOI: https://doi.org/10.1124/dmd.32.11.1218
Back to top

In this issue